MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Avadel Pharmaceuticals plc Deferred Revenue 2011-2026 | AVDL
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Avadel Pharmaceuticals plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 114 K | 2.01 M | 2.22 M | 5.12 M | 1.34 M | 1.38 M | 1.19 M | 4.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.12 M | 114 K | 2.27 M |
Quarterly Deferred Revenue Avadel Pharmaceuticals plc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 114 K | - | - | - | 2.01 M | 1.93 M | 2.46 M | 1.62 M | 2.22 M | 2.22 M | 2.22 M | 2.22 M | 5.12 M | 5.12 M | 5.12 M | 5.12 M | 1.34 M | 612 K | 954 K | 157 K | 1.26 M | 1 M | 190 K | - | 614 K | - | 2.49 M | 2.98 M | 2.84 M | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.12 M | 114 K | 2.16 M |
Deferred Revenue of other stocks in the Drug manufacturers industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Adamis Pharmaceuticals Corporation
ADMP
|
27.8 K | - | 0.86 % | $ 117 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
49 K | - | 7.5 % | $ 6.35 M | USA |
 |
Assertio Holdings
ASRT
|
200 K | $ 18.02 | - | $ 115 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
85.4 M | - | - | $ 754 M | USA |
 |
Catalent
CTLT
|
250 M | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
545 K | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
6 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
600 K | - | - | $ 28.9 M |  Irlanda |
 |
Athenex
ATNX
|
2.82 M | - | -23.39 % | $ 1.76 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
207 K | $ 3.09 | -0.64 % | $ 43.4 M | USA |
 |
HEXO Corp.
HEXO
|
8.21 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Bausch Health Companies
BHC
|
26 M | $ 5.6 | 3.9 % | $ 2.04 B | Canada |
 |
Harrow Health
HROW
|
788 K | $ 35.93 | -3.65 % | $ 1.32 B | USA |
 |
Aurora Cannabis
ACB
|
27 M | $ 3.43 | -1.44 % | $ 86.3 M | Canada |
 |
Evolus
EOLS
|
11.5 M | $ 4.27 | 0.71 % | $ 275 M | USA |
 |
Emergent BioSolutions
EBS
|
27.2 M | $ 7.96 | -5.8 % | $ 408 M | USA |
 |
Tilray
TLRY
|
23.7 M | $ 6.57 | -2.23 % | $ 4.06 B | Canada |
 |
Pacira BioSciences
PCRX
|
102 K | $ 23.79 | -0.13 % | $ 1.1 B | USA |
 |
Veru
VERU
|
400 K | $ 2.38 | -2.06 % | $ 321 M | USA |
 |
ProPhase Labs
PRPH
|
2.5 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
1 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
543 K | - | -4.76 % | $ 65.3 M | USA |
 |
cbdMD
YCBD
|
503 K | $ 0.68 | 4.01 % | $ 2.93 M | USA |
 |
SCYNEXIS
SCYX
|
235 K | $ 1.0 | 0.81 % | $ 49.9 M | USA |
 |
OptiNose
OPTN
|
160 K | - | - | $ 1.08 B | USA |
 |
Solid Biosciences
SLDB
|
10.4 M | $ 8.02 | -0.99 % | $ 702 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
641 K | $ 2.28 | -5.39 % | $ 2.83 M | USA |
 |
Zomedica Corp.
ZOM
|
368 K | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
172 K | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
46 K | $ 0.91 | -2.17 % | $ 32.7 M | USA |
 |
China Pharma Holdings
CPHI
|
112 K | $ 0.63 | -3.82 % | $ 2.7 M |  China |
 |
TherapeuticsMD
TXMD
|
523 K | $ 2.07 | 0.98 % | $ 23.9 M | USA |